Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
111.00
+10.00 (9.90%)
Apr 29, 2026, 1:30 PM CST

TPE:6919 Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Market Capitalization
157,193240,25094,36523,5407,528-
Upgrade
Market Cap Growth
13.54%154.60%300.87%212.69%--
Upgrade
Enterprise Value
152,305233,73884,68522,6946,297-
Upgrade
Last Close Price
101.00155.0061.5019.136.11-
Upgrade
PS Ratio
4132.426316.212123.71604.64587.23-
Upgrade
PB Ratio
16.7925.539.736.296.47-
Upgrade
P/TBV Ratio
16.7925.539.736.296.47-
Upgrade
EV/Sales Ratio
-6145.021905.86582.91491.18-
Upgrade
Debt / Equity Ratio
000.000.010.030.06
Upgrade
Net Debt / Equity Ratio
-0.52-0.52-1.00-0.99-0.93-0.87
Upgrade
Net Debt / EBITDA Ratio
6.967.0913.887.483.582.60
Upgrade
Net Debt / FCF Ratio
14.0510.9818.148.534.214.44
Upgrade
Asset Turnover
0.000.000.010.020.010.03
Upgrade
Inventory Turnover
2.194.017.045.992.252.41
Upgrade
Quick Ratio
43.95106.97183.4250.4823.0415.00
Upgrade
Current Ratio
45.21109.71184.0250.8123.4115.26
Upgrade
Return on Equity (ROE)
-3.00%-3.68%-8.76%-19.92%-31.64%-64.89%
Upgrade
Return on Assets (ROA)
-4.73%-4.59%-6.59%-12.68%-20.53%-30.68%
Upgrade
Return on Capital Employed (ROCE)
-7.70%-7.50%-7.40%-13.70%-27.00%-34.30%
Upgrade
Earnings Yield
-0.18%-0.15%-0.62%-2.08%-3.80%-
Upgrade
FCF Yield
-0.22%-0.18%-0.56%-1.84%-3.41%-
Upgrade
Buyback Yield / Dilution
-5.54%-7.94%-15.40%-5.77%-27.35%-23.49%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.